HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Anne Fung MD
- Study ID
- NCT01189019
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Macular Degeneration
- Retinal Pigment Epithelial Detachment
- Wet Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- ranibizumab — DRUG2mg intravitreal injection monthly
- ranibizumab — DRUG2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
Study Details
In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are collecting groups of patients who either do not or only partially respond to anti-VEGF therapy. This study will evaluate the efficacy and safety of 2mg ranibizumab specifically for patients with fibrovascular PEDs that have not resolved following at least 6 consecutive injections of ranibizumab or bevacizumab over the previous 12 months. The investigators hypothesize that the 2mg dose will be able to completely eliminate the persistent PEDS in these patients.
Key Dates
- First listed
- Aug 26, 2010
- Start date
- Aug 31, 2010
- Status verified
- Mar 2016
- Primary completion
- Mar 31, 2013
- Completion
- Mar 31, 2013
Study Design
- Enrollment
- 40 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1 - 2mg ranibizumab monthly2mg ranibizumab monthly
- Active Comparator: Group 2 - 2mg x 3 then PRN
Primary Outcome Measure
Mean change in visual acuity from baseline to 24 months [ Time Frame: 24 months ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Pacific Eye Associates | San Francisco | California | 94115 | - |
| Retina Associates of Kentucky | Lexington | Kentucky | 40509 | - |
| Tennessee Retina | Nashville | Tennessee | 37203 | - |
Find similar trials in San Francisco, CA
By condition
By specialty
Related Studies
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- Quest to Analyze One Thousand Humans MeditatingEnrolling By Invitation · Tobias Moeller-Bertram · Palm Desert, California
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)PHASE2 · Recruiting · Janssen Research & Development, LLC · Tucson, Arizona
- A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic AtrophyRecruiting · Astellas Pharma Global Development, Inc. · Phoenix, Arizona